Skip to content

Impact of a Simple Automated Best Practice Alert (BPA) on Quantity and Quality of In-hospital Antibiotic Use in a Tertiary and Three Secondary Hospitals

Impact of a Simple Automated Best Practice Alert (BPA) on Quantity and Quality of In-hospital Antibiotic Use - a Stepped-wedge, Cluster Randomized, Controlled Trial

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07115966
Acronym
TARGET
Enrollment
58
Registered
2025-08-11
Start date
2025-08-01
Completion date
2026-07-31
Last updated
2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibiotic Prescriptions, In-Patient Treatment

Keywords

best practice alert, quanlity and quantity of antibiotic use, in-patients

Brief summary

The goal of the stepped-wedge cluster-randomized trial is to assess the impact of an antimicrobial stewardship intervention: a simple, automated Best Practice Alert (BPA) that reminds prescribers to reevaluate antibiotic therapy after 72 hours (or 24 hours for prophylaxis), in accordance with guideline recommendations. The primary hypothesis is that this simple BPA reduces antibiotic use in terms of quantity (amount and duration) and quality (spectrum breadth), measured by days of antibiotic spectrum coverage at the patient level (primary outcome), as well as at both patient and cluster levels using various metrics of antibiotic use. The trial will introduce the BPA in a stepwise manner, with all wards implementing it by the end. It will compare the intervention period to the baseline (pre-intervention) and control periods.

Interventions

BEHAVIORALComputerized decision support by best practice alert (BPA)

The antimicrobial stewardship intervention encourages prescribers by a simple alert to follow guidelines for reviewing antimicrobial prescriptions after a set timeframe for potential de-escalation to targeted therapy or discontinuation of the antibiotics, as recommended by national and international guidelines. An automated simple BPA will trigger after an antibiotic prescription with therapeutic indication (72 hours) or surgical prophylaxis (24 hours, reminding prescribers to reassess treatment for possible de-escalation, adaption to targeted therapy, or cessation. If ignored, the prescription remains unchanged, but the alert will continue until addressed. Prescribers must select reasons for not changing the prescription, such as pending microbiology results. The control group corresponds to the inpatient wards not yet receiving the BPA, where antibiotics are managed according to standard-of-care.

Sponsors

Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

Cluster allocation will also be blinded to the wards and prescribers; however, prescribers may become aware of their cluster assignment when working across different wards in both intervention and control clusters, based on whether or not they receive the BPA.

Intervention model description

Wards will be cluster-randomized according to specialty and antibiotic use (DASC/PA), based on retrospective data. The BPA will be activated in a stepwise manner for each cluster every two months over a 12-month period. By the end of the study, the BPA will be active in all participating wards.

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

• All inpatient wards with at least 50 PA/year, except those listed in the

Design outcomes

Primary

MeasureTime frameDescription
Days of antibiotic spectrum coverage (DASC) per patient admission (PA)12 monthsOverall score of days of antibiotic spectrum coverage per patient admission. The score is composed of the breadth of the bacterial spectrum covered by the administered antibiotic (according to Kakiuchi 2022 - the broader the antibiotic spectrum, the higher the score), summed over the number of days the antibiotic is given. Accordingly, there are no maximum or minimum values

Secondary

MeasureTime frameDescription
Days of treatment (DOT) per 100 patient days (PD) and per patient admission on ward level12 monthsOverall days of treatment (DOT) per 100 patient days (PD) and per patient admission (PA) on ward level
Defined daily doses (DDD) per 100 patient days (PD) and per patient admission (PA)12 monthsOverall defined daily doses) per 100 patient days (PD) and per patient admission (PA) on ward level. Standard metrics recommended by WHO for international benchmarking.
Antibiotic (AB) days per patient admission (PA)12 monthsNo of days an AB per PA gives the proportion of days antibiotics have been applicated, irrespective of single, double, triple combinations, in relation to total PA
In hospital mortality12 monthsAll cause in hospital mortality
Hospital length of stay (LOS)12 months
Days of antibiotic spectrum coverage (DASC) per patient antibiotic day (PAD)12 monthsOverall score of antibiotic spectrum coverage per patient antibiotic day. The score is composed of the breadth of the bacterial spectrum covered by the administered antibiotic (according to Kakiuchi 2022 - the broader the antibiotic spectrum, the higher the score), summed over the number of days the antibiotic is given. Accordingly, there are no maximum or minimum values.
Patient admission to IMC/ICU from studied wards12 monthsNumber and proportion of patient admissions to IMC/ICU from studied wards
Number of Infectious diseases (ID) consultation per patient admission (PA)12 months
In hospital C. difficile infection incidence within hospital stay per patient admission (PA) and per 100 patient days (PD)12 months
Inhospital incidence of multi-drug-resistant-organisms (MDRO) detection per100 patient days (PD) or per patient admission (PA)12 months
Unplanned readmission within first 30 days after discharge12 months

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026